Oral minoxidil is approved by the U.S. Food and Drug Administration (FDA) to treat high blood pressure. In some cases, healthcare providers prescribe oral minoxidil off-label for hair loss.

Zealthy offers FDA-approved treatments tailored to specific hair loss patterns. Its combination of Finasteride and Minoxidil gel produces powerful results for overall thinning, with 90% of users ...

In 1979, minoxidil tablets were FDA-approved as a treatment for high blood pressure (hypertension). When used for high blood pressure, it’s sold under the brand name Loniten. There was another ...

Cat people such as myself will sacrifice anything for their pet. We give up fresh flowers (too many are toxic to cats), ...

It’s the first of a new class of analgesics to be approved in over 20 years, and, importantly, it isn’t addictive. On the 30th of January 2025, the FDA approved 50-mg tablets of the novel ...

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

Share on Pinterest The FDA has approved an esketamine nasal spray for the treatment of depression cases that do not respond to other therapeutic approaches. Image credit: Koldunov/Getty Images.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval ...

Ozempic is already widely used and was first FDA-approved in 2017 to treat type 2 diabetes. The medication — taken weekly by injection in the thigh, stomach or arm — is a brand name for ...

GRAFAPEX™ (treosulfan) with fludarabine is FDA-approved for AML and MDS patients undergoing alloHSCT, showing improved overall survival compared to busulfan. Common side effects include ...

FDA approval of PATHWAY HER2 (4B5) test expands diagnostic capabilities for HER2-ultralow metastatic breast cancer, enabling targeted treatment with trastuzumab deruxtecan. HER2-ultralow ...